<DOC>
	<DOCNO>NCT00004870</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Gene therapy oblimersen may make tumor cell sensitive chemotherapy drug . Combining irinotecan oblimersen may kill tumor cell . PURPOSE : Phase I/II trial study effectiveness combine oblimersen irinotecan treating patient metastatic recurrent colorectal cancer .</brief_summary>
	<brief_title>Olimersen Irinotecan Treating Patients With Metastatic Recurrent Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine dose-limiting toxic effect maximum tolerate dose augmerosen ( G3139 ) administer combination irinotecan patient unresectable metastatic recurrent colorectal cancer . II . Determine quantitative qualitative toxicity drug combination patient population . III . Assess plasma pharmacokinetics combination patient . IV . Document antitumor activity drug combination patient phase II study . V. Determine relevant biologic endpoint treatment tumor biopsy prior therapy G3139 two dose level assess pharmacokinetic pharmacodynamic correlation . OUTLINE : This dose-escalation , multicenter study . Patients receive augmerosen ( G3139 ) IV continuously day 1-7 irinotecan IV 90 minute day 6 . Treatment continue every 21 day absence unacceptable toxicity disease progression . Cohorts 3-6 patient receive escalate dos G3139 irinotecan maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . Once MTD determine , additional patient accrue receive treatment G3139 irinotecan recommend phase II dose . Patients follow every 30 day toxicity resolve . PROJECTED ACCRUAL : A maximum 18 patient accrued phase I portion study . A maximum 55 patient accrue phase II portion study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm unresectable metastatic recurrent adenocarcinoma colon rectum No brain metastasis unless previously treat , asymptomatic , stable dose decadron , CT/MRI scan demonstrates evidence edema Phase I : Measurable evaluable disease Phase II : Measurable disease Evidence +1 bcl2 expression immunohistochemical stain pathologic material PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : Platelet count least 100,000/mm3 Hemoglobin least 9.0 g/dL Absolute granulocyte count least 1,500/mm3 Hepatic : Bilirubin great 1.5 mg/dL AST/ALT great 3 time upper limit normal ( ULN ) ( 5 time ULN liver metastasis ) PT/PTT normal Renal : Creatinine great 1.5 mg/dL Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No active infection No serious concurrent systemic disorder would preclude study treatment PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunotherapy Chemotherapy : At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover No concurrent chemotherapy Phase I : At least 4 week since prior irinotecan recover Phase II : No 2 prior fluorouracilbased regimens metastatic disease No prior irinotecan Endocrine therapy : See Disease Characteristics No concurrent anticancer hormonal therapy Radiotherapy : No concurrent radiotherapy Surgery : See Disease Characteristics Other : No concurrent experimental medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma rectum</keyword>
</DOC>